VBI Vaccines Inc.

VBI Vaccines — Technical Presentation (June 2020)

7 slides from VBI Vaccines's technical presentation, Jun 22, 2020

  1. Slide 1: Immunologic, tumor, and clinical data discussion

    \ MMi, oom > VBI VACCINES ome Immunologic, tumor, and clinical data discussion with: Allen Waziri, M.D. hd Member, VBI’s GBM/Immuno-Oncology Scientific & Clinical Advisory Board CEO and Co-Founder, iCE Neurosystems \ Former Director of the Brain Tumor Program, Inova Neuroscience Institute David E. A

  2. Slide 2: Disclosure Statements

    Disclosure Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information wit

  3. Slide 3: Clinical Outcomes From Ongoing Phase I/IIa Clinical Study of VBI-1901 in Recurrent GBM Patients

    Clinical Outcomes From Ongoing Phase I/Ila Clinical Study of VBI-1901 in Recurrent GBM Patients Part A : Dose-Escalation Phase — Recurrent GBM (any # of recurrences) Study Arm 1: Low Dose (n=6) * Enrollment completed December 2018 (n=18) O.4uB +t GM:CSE + 12-month overall survival (OS) rate of 83% i

  4. Slide 4: Identified Biomarker from Part A and B

    Identified Biomarker from Part A and B: Normal Baseline CD4+/CD8+ Ratio is Associated with Tumor Responses CD4+/CD8+ T Cell Ratio Change in Tumor Size Over Time Ratio among CD3+T cells Tumor Tumor Progression Response (n=20) (n=6) Tumor size change vs. baseline (%) 120 . 400 @ Stable Disease ® Parti

  5. Slide 5: MRI of Patient with Partial Tumor Response

    MRI of Patient with Partial Tumor Response Patient (04-002) Baseline Week 24 hs NASDAQ: VBIV

  6. Slide 6: Conclusions

    nn ee Conclusions EG oh 6 tumor responses, including one partial response, seen to-date in Part A and B of the ongoing Phase I/Ila clinical study of VBI-1901 in recurrent GBM patients The CD4+/CD8+ biomarker identified may be used in a follow-on trial to help enrich for and predict patients most lik

  7. Slide 7: VBI Vaccines Inc. contact details

    VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected]

VBI Vaccines — Technical Presentation (June 2020) on 6ix